These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 19620385)

  • 1. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
    Wang DD; Zhang S; Zhao H; Men AY; Parivar K
    J Clin Pharmacol; 2009 Sep; 49(9):1012-24. PubMed ID: 19620385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.
    Zhang S; Shi R; Li C; Parivar K; Wang DD
    J Clin Pharmacol; 2012 Jan; 52(1):18-28. PubMed ID: 21233304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic relationships for analgesics.
    Suri A; Estes KS; Geisslinger G; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):307-23. PubMed ID: 9266286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
    Ng CM; Bruno R; Combs D; Davies B
    J Clin Pharmacol; 2005 Jul; 45(7):792-801. PubMed ID: 15951469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of body weight and body surface area in dosing of anticancer agents in adult patients].
    Levêque D
    Bull Cancer; 2007 Jul; 94(7):647-51. PubMed ID: 17723945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.
    Pai MP
    Pharmacotherapy; 2012 Sep; 32(9):856-68. PubMed ID: 22711238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
    Mathijssen RH; de Jong FA; Loos WJ; van der Bol JM; Verweij J; Sparreboom A
    Oncologist; 2007 Aug; 12(8):913-23. PubMed ID: 17766650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of fixed dosing of new anticancer agents in phase I studies.
    Levêque D
    Anticancer Res; 2008; 28(5B):3075-7. PubMed ID: 19031959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.
    Toutain PL; Lees P
    J Vet Pharmacol Ther; 2004 Dec; 27(6):467-77. PubMed ID: 15601441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.
    Booth BP; Rahman A; Dagher R; Griebel D; Lennon S; Fuller D; Sahajwalla C; Mehta M; Gobburu JV
    J Clin Pharmacol; 2007 Jan; 47(1):101-11. PubMed ID: 17192508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
    Ng CM; Lum BL; Gimenez V; Kelsey S; Allison D
    Pharm Res; 2006 Jun; 23(6):1275-84. PubMed ID: 16715358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
    Xu Y; Langevin BA; Zhou H; Xu Z
    J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dosing strategy for pembrolizumab for oncology indications.
    Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
    J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing rationale for fixed-dose combinations in children: shooting from the hip?
    Cella M; Kloprogge F; Danhof M; Della Pasqua O
    Clin Pharmacol Ther; 2012 Apr; 91(4):718-25. PubMed ID: 22398964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
    Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid.
    Delavenne X; Laporte S; Demasles S; Mallouk N; Basset T; Tod M; Girard P; Mismetti P
    Fundam Clin Pharmacol; 2009 Feb; 23(1):127-35. PubMed ID: 19267776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.